Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 19323 results found since Jan 2013.
Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
This study serves as an important reminder that spontaneous reports should only be used with great caution to quantify and compare safety profiles across products over time. The observed variability in reporting patterns and heterogeneity of PML cases presents challenges to such comparisons. Lumping uncharacterized PML reports together without taking these differences into account may result in biased comparisons and flawed conclusions about differential safety.
PMID: 26347128 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - September 8, 2015 Category: Drugs & Pharmacology Authors: Vermeer NS, Straus S, Mantel-Teeuwisse AK, Hidalgo-Simon A, Egberts A, Leufkens H, De Bruin ML Tags: Clin Pharmacol Ther Source Type: research
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in ...
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Smolen, J. S., Landewe, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., de Wit, M., Aletaha, D., Betteridge, N., Bijlsma, J. W. J., Boers, M., Buttgereit, F., Combe, Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Recommendation Source Type: research
Autoimmune Encephalitis in the ICU: Serological Spectrum, Clinical Courses, Complications and Outcomes (I4-5A)
CONCLUSIONS: Autoimmune encephalitis needs to be considered in neural antibody negative cases. Even when severe, good outcomes may occur in ICU-managed autoimmune encephalitis patients. Comprehensive diagnostic evaluation should be pursued to facilitate timely treatment.Disclosure: Research support from MedImmune for a laboratory diagnostics study. Dr. Mittal has nothing to disclose. Dr. Hocker has received personal compensation for activities with Continuum Pharma. Dr. Pittock's institution has received compensation for activities with Alexion Pharmaceuticals, Medimmune, and Chugai Pharma. Dr. Pittock and his institution ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: McKeon, A., Mittal, M., Hocker, S., Pittock, S., Wijdicks, E., Rabinstein, A. Tags: Infectious, Paraneoplastic, and Autoimmune Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis Poster Presentations Source Type: research
Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting
Rituximab has broad and increasing application in rheumatic diseases. It is known from lymphoma studies that natural killer (NK) cells can lyse rituximab-coated transformed B cells. However, the role of NK cel...
Source: Arthritis Research and Therapy - September 15, 2016 Category: Rheumatology Authors: Wolfgang Merkt, Hanns-Martin Lorenz and Carsten Watzl Source Type: research
Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells
One of the main problems in B cell lymphoma treatment is severe adverse effects and low therapeutic efficacy resulting from systemic chemotherapy. A pH-sensitive controlled drug release system based on mesopor...
Source: Journal of Experimental and Clinical Cancer Research - February 6, 2017 Category: Cancer & Oncology Authors: Shoubing Zhou, Dan Wu, Xiaodong Yin, Xiaoxiao Jin, Xiu Zhang, Shiya Zheng, Cailian Wang and Yanwen Liu Source Type: research
B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients
B cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but...
Source: Arthritis Research and Therapy - May 18, 2017 Category: Rheumatology Authors: Jens Thiel, Marta Rizzi, Marie Engesser, Ann-Kathrin Dufner, Arianna Troilo, Raquel Lorenzetti, Reinhard E. Voll and Nils Venhoff Source Type: research
Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. ...
Source: Infectious Agents and Cancer - June 7, 2018 Category: Cancer & Oncology Authors: Mubarak M. Al-Mansour, Saif A. Alghamdi, Musab A. Alsubaie, Abdullah A. Alesa and Muhammad A. Khan Tags: Research Article Source Type: research
New agents and regimens for diffuse large B cell lymphoma
As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...
Source: Journal of Hematology and Oncology - December 14, 2020 Category: Hematology Authors: Liang Wang, Lin-rong Li and Ken H. Young Tags: Review Source Type: research
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
Rituximab is used for the treatment of active rheumatoid arthritis. In the present study, we examined the long-term flare risk and safety of reduced doses of rituximab.
Source: Arthritis Research and Therapy - June 2, 2022 Category: Rheumatology Authors: Antonios Bertsias, Nestor Avgoustidis, Ioannis Papalopoulos, Argyro Repa, Nikolaos Kougkas, Eleni Kalogiannaki, Georgios Bertsias, Irini Flouri and Prodromos Sidiropoulos Tags: Research article Source Type: research
Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study
In Switzerland, rituximab (RTX) is licenced for the treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV) but is frequently used off-label to treat other auto-immune diseases (AID), espec...
Source: Arthritis Research and Therapy - June 1, 2023 Category: Rheumatology Authors: Alexandre Dumusc, Fahad Alromaih, Matthieu Perreau, Thomas H ügle, Pascal Zufferey and Diana Dan Tags: Research Source Type: research
Fever and confusion in a returning soldier
A 36–year–old army engineer returned from a 6–week deployment in Afghanistan. He had complained of upper respiratory tract infection even before his travel. On return he was found to be increasingly sleepy and later developed unsteadiness, slurred speech and confusion. His initial blood tests were normal, with CSF and MRI suggesting signs of encephalitis. He continued to deteriorate, requiring intubation and ventilation. Several bacterial, viral, protozoal and fungal tests were negative. He developed pancytopenia requiring frequent packed red cell and platelet transfusions. Spleen was found to be marginal...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Chandratheva, A., Singh, A. R., Sturman, S., Chaganti, S., Jacob, S. Tags: Immunology (including allergy), HIV/AIDS, Tropical medicine (infectious diseases), Drugs: CNS (not psychiatric), Epilepsy and seizures, Infection (neurology), Memory disorders (psychiatry) Association of British Neurologists (ABN) joint meeting with the Source Type: research
Hyperexcitable brain and refractory coeliac disease: a new syndrome
We present here the clinical and detail electrophysiological features of the largest series of 7 patients and further characterise and hence rename the syndrome as progressive cortical hyperexcitability with ataxia and refractory coeliac disease.
The 7 patients (5 male, 2 female) were identified from a cohort of 540 patients with neurological manifestations of GRD that regularly attend our gluten/neurology clinic. The mean age at onset of the neurological symptoms was 58 years (range 46 to 76). Unlike myoclonic ataxia (eg in the context of opsoclonus myoclonus ataxia syndrome) the myoclonic tremor in these patients was ini...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Hadjivassiliou, M., Fotheringham, J., Sanders, D., Grunewald, R., Hoggard, N., Sarrigiannis, P. Tags: Immunology (including allergy), Brain stem / cerebellum, Cranial nerves, Drugs: CNS (not psychiatric), Epilepsy and seizures, Headache (including migraine), Pain (neurology), Ophthalmology Association of British Neurologists (ABN) joint meeting with the Source Type: research
Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange
Case history A 38-year-old woman with no significant past medical history presented with a generalised tonic–clonic seizure. The patient was afebrile and general physical and neurological examinations were normal. MRI of the brain revealed an irregular mass in the right temporal lobe with T2-weighted and fluid-attenuated inversion recovery (FLAIR) signal hyperintensity and heterogeneous enhancement after the administration of gadolinium (figure 1A–D). Laboratory investigations included normal blood count, liver enzymes, serum creatinine, angiotensin converting enzyme and erythrocyte sedimentation rate (ESR). Se...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 13, 2013 Category: Neurosurgery Authors: Sempere, A. P., Feliu-Rey, E., Sanchez-Perez, R., Nieto-Navarro, J. Tags: Immunology (including allergy), HIV/AIDS, Cranial nerves, Drugs: CNS (not psychiatric), Epilepsy and seizures, Headache (including migraine), Multiple sclerosis, Neurooncology, Pain (neurology), CNS cancer, Ophthalmology, Radiology, Surgical diagnostic te Source Type: research
The use of biologicals in cutaneous allergies – present and future
In conclusion, although currently only one biological is approved in chronic urticaria, there is hope that a rapid better understanding of individual disease factors will support the development of other novel drugs in this field.
Source: Current Opinion in Allergy and Clinical Immunology - October 1, 2014 Category: Allergy & Immunology Tags: SKIN ALLERGY: Edited by Torsten Zuberbier and Thomas Werfel Source Type: research
Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques Host Response and Inflammation
Although recent studies in mice have shown that components of B cell and humoral immunity can modulate the immune responses against Mycobacterium tuberculosis, the roles of these components in human and nonhuman primate infections are unknown. The cynomolgus macaque (Macaca fascicularis) model of M. tuberculosis infection closely mirrors the infection outcomes and pathology in human tuberculosis (TB). The present study used rituximab, an anti-CD20 antibody, to deplete B cells in M. tuberculosis-infected macaques to examine the contribution of B cells and humoral immunity to the control of TB in nonhuman primates during the...
Source: Infection and Immunity - April 21, 2016 Category: Infectious Diseases Authors: Phuah, J., Wong, E. A., Gideon, H. P., Maiello, P., Coleman, M. T., Hendricks, M. R., Ruden, R., Cirrincione, L. R., Chan, J., Lin, P. L., Flynn, J. L. Tags: Host Response and Inflammation Source Type: research
